Ethyl N-[5-[[5-(N-phenylanilino)-6-pyrrolidin-1-yl-3-pyridinyl]sulfanyl]-3-pyridinyl]carbamate
C29H29N5O2S — CID 122526517
Data last refreshed: (MolForge compound catalog, from PubChem)
About Ethyl N-[5-[[5-(N-phenylanilino)-6-pyrrolidin-1-yl-3-pyridinyl]sulfanyl]-3-pyridinyl]carbamate
Ethyl N-[5-[[5-(N-phenylanilino)-6-pyrrolidin-1-yl-3-pyridinyl]sulfanyl]-3-pyridinyl]carbamate (PubChem CID 122526517) has the molecular formula C29H29N5O2S and a molecular weight of 511.65 g/mol. Its IUPAC name is ethyl N-[5-[[5-(N-phenylanilino)-6-pyrrolidin-1-yl-3-pyridinyl]sulfanyl]-3-pyridinyl]carbamate.
Molecular Properties
| Compound Name | Ethyl N-[5-[[5-(N-phenylanilino)-6-pyrrolidin-1-yl-3-pyridinyl]sulfanyl]-3-pyridinyl]carbamate |
|---|---|
| PubChem CID | 122526517 |
| Molecular Formula | C29H29N5O2S |
| Molecular Weight | 511.65 g/mol |
| Exact Mass | 511.20 |
| IUPAC Name | ethyl N-[5-[[5-(N-phenylanilino)-6-pyrrolidin-1-yl-3-pyridinyl]sulfanyl]-3-pyridinyl]carbamate |
| SMILES | CCOC(=O)Nc1cncc(Sc2cnc(N3CCCC3)c(N(c3ccccc3)c3ccccc3)c2)c1 |
| InChI | InChI=1S/C29H29N5O2S/c1-2-36-29(35)32-22-17-25(20-30-19-22)37-26-18-27(28(31-21-26)33-15-9-10-16-33)34(23-11-5-3-6-12-23)24-13-7-4-8-14-24/h3-8,11-14,17-21H,2,9-10,15-16H2,1H3,(H,32,35) |
| InChIKey | AIUHSXLJADKVPW-UHFFFAOYSA-N |
| XLogP | 7.27 |
| TPSA | 70.59 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 37 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 511.65 |
| LogP ≤ 5 | 7.27 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 122526517 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.